

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

EFFECTIVE SUPPRESSION OF HIV-1 GENE EXPRESSION BY A MAMMALIAN tRNA 3' PROCESSING ENDORIBONUCLEASE AND EXTERNAL GUIDE SEQUENCE OLIGOZYMES

Michiko Kitano^a; Jaco S. Barnor^b; Naoko Miyano-Kurosaki^b; Yumihiko Endo^a; Masakazu Yukita^a; Hiroaki Takeuchi^c; Yutaka Tamura^b; Kazuyuki Takai^a; Masayuki Nashimoto^d; Hiroshi Takaku^a

^a Department of Industrial Chemistry, Chiba Institute of Technology, Chiba, Japan ^b High Technology Research Center, Chiba Institute of Technology, Chiba, Japan ^c Department of Virology, Tohoku University School of Medicine, Sendai, Japan ^d Department of Chemistry Biochemistry, Brigham Young University, Provo, Utah, U.S.A.

Online publication date: 31 March 2001

To cite this Article Kitano, Michiko , Barnor, Jaco S. , Miyano-Kurosaki, Naoko , Endo, Yumihiko , Yukita, Masakazu , Takeuchi, Hiroaki , Tamura, Yutaka , Takai, Kazuyuki , Nashimoto, Masayuki and Takaku, Hiroshi(2001) 'EFFECTIVE SUPPRESSION OF HIV-1 GENE EXPRESSION BY A MAMMALIAN tRNA 3' PROCESSING ENDORIBONUCLEASE AND EXTERNAL GUIDE SEQUENCE OLIGOZYMES', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 719 — 722

To link to this Article: DOI: 10.1081/NCN-100002621

URL: <http://dx.doi.org/10.1081/NCN-100002621>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

EFFECTIVE SUPPRESSION OF HIV-1 GENE EXPRESSION BY A MAMMALIAN tRNA 3' PROCESSING ENDORIBONUCLEASE AND EXTERNAL GUIDE SEQUENCE OLIGOZYMES

**Michiko Kitano,¹ Jaco S. Barnor,² Naoko Miyano-Kurosaki,²
Yumihiko Endo,¹ Masakazu Yukita,¹ Hiroaki Takeuchi,³
Yutaka Tamura,² Kazuyuki Takai,^{1,2} Masayuki Nashimoto,⁴
and Hiroshi Takaku^{1,2,*}**

¹Department of Industrial Chemistry and

²High Technology Research Center, Chiba Institute of Technology,
2-17-1 Tsudanuma, Narashino, Chiba 275-0016, Japan

³Department of Virology, Tohoku University School of Medicine,
2-1 Seiryō-machi, Aoba-ku, Sendai 980-8575, Japan

⁴Department of Chemistry and Biochemistry,
Brigham Young University, Provo, Utah 84602

ABSTRACT

We examined the suppression of virus expression by cleavage of the HIV-1 RNA gene using a mammalian tRNA 3' processing endoribonuclease and an External Guide Sequence Oligozyme (EGS) *in vivo*. We constructed an EGS expression vector that used the tRNA^{met} promoter as an expression cassette for EGS. The EGS expression vector was targeted to the upstream region of gag, region. The EGS expression vector was co-transfected into COS cells with the HIV-1 gene plasmid vector. As compared with the EGS non-expressing cells and the EGS expressing cells, the EGS expressing cells with the targeted gag start codon had a clearly decreased amount of the HIV-1 gag p24 protein. The EGS expressing cells with the targeted gag start codon showed effective suppression of HIV-1 gene expression. Thus, these studies describe novel gene targeting agents for the inhibition of gene expression and antiviral activity.

*Corresponding author. Fax: +81-471-8764; E-mail: takaku@ic.it-chiba.ac.jp

INTRODUCTION

Antisense technology is a promising targeting approach for use in basic research and clinical therapeutic applications. The gene targeting agents can be a conventional antisense oligonucleotide, an antisense catalytic molecule (ribozyme or DNA enzyme), or an antisense molecule with an additional (guide) sequence that targets the mRNA for degradation by endogenous RNases (1,2).

Mammalian tRNA 3' processing enzymes (3' tRNase) have been reported. These enzymes can remove a 3' trailer after the discriminator nucleotide from various precursor tRNAs (3). It has been reported that the enzyme could be converted to a highly specific endoribonuclease using tRNAs that have been artificially 3' truncated. Indeed, the 3' tRNase can cleave a 3' half tRNA (consisting of the 3' trailer) in the presence of a 5' half tRNA (EGS, consisting of the 5' end) (4).

Using a two half-tRNA system, we demonstrated that the 3' tRNase could recognize and cleave pre-tRNA containing various HIV-1 RNA targets *in vivo* (Fig. 1). In this study, we describe the intracellular inhibition of HIV-1 expression using EGS.

RESULTS AND DISCUSSION

At first, the EGS was inserted into pSV2neo, which contained the sequence of the tRNA^{met} promoter region. The EGS base sequence was confirmed using the ABI PRISMTM 310 Genetic Analyzer (PE Biosystems). The EGS expression vectors were transfected into COS cells with the HIV-1 genome, and the suppression of HIV-1 gene expression was examined. Figure 2 shows the result, regarding the expression rate of HIV-1 p24. As compared with the EGS non-expressing vector and the EGS expressing cells, the EGS expressing cell with the targeted gag start codon had a clearly decreased amount of the p24 protein. This region showed more effective suppression of HIV-1 gene expression than the EGS expression vector with the targeted gag p24 region. We thought that the EGS-gag p24 was not




Figure 1. Specific cleavage of target RNAs with EGS by mammalian tRNA 3' processing endoribonuclease.






Figure 2. Rate of HIV-1 p24 expression.

complementary to the target RNA, and did not form a pre-tRNA-like complex. For this reason, EGS-gag p24 showed no 3'-endoribonuclease activity. Therefore, the EGS expression vector with the targeted gag start codon region is useful as a gene inactivating agent of HIV-1.

EXPERIMENTAL SECTION

The EGS expression vector that uses the tRNA^{met} promoter was constructed as follows. The EGS was designed to be targeted to the gag region of HIV-1 RNA. EGS antisense and sense oligonucleotides that encoded the terminator were annealed and ligated into the *Kpn*_*Bam* H_₁ sites of pSV2neo, which contained the sequence of the tRNA^{met} promoter region. These plasmids were isolated from *E.coli* XL2-blue and were purified on a JETSTAR Plasmid Purification System (GENOMED Inc.). These EGS base sequences were analyzed using an ABI PRISMTM 310 Genetic Analyzer (PE Biosystems).

COS cells were grown in RPMI 1640 (SIGMA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 37°C in a 5% CO₂ atmosphere. Plasmids expressing the EGS, the luciferase gene, and other parts of the HIV-1 genome (except *env* and *nef*) were co-transfected into COS cells. The COS cells (20 × 10⁴ cells/2 ml) were prepared and transfected with the EGS expression vector using the FuGENETM 6 transfection reagent (Roche Diagnostics K.K.). After 48 hours, the COS cells were harvested and the luciferase activities and the amounts of HIV-1 gag p24 in these cells were measured.

ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for High Technology Research and Scientific Research, No. 09309011, from the Ministry of Education, Science, Sports, and Culture, Japan.



REFERENCES

1. Plehn-Dujowich, D.; Altman, S. *Proc Natl Acad Sci USA.*, **1998**, **95**, 7327–7332.
2. Yuan, Y.; Altman, S. *Science*, **1994**, **263**, 1269–1273.
3. Nashimoto, M. *Nucleic Acids Res.*, **1997**, **25**, 1148–1154.
4. Nashimoto, M. *RNA*, **1996**, **2**, 523–534.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002621>